Regeneron (REGN) Gets a Hold Rating from Cantor Fitzgerald

By Jason Carr

In a report released today, Alethia Young from Cantor Fitzgerald assigned a Hold rating to Regeneron (REGNResearch Report), with a price target of $441. The company’s shares closed yesterday at $421.04, close to its 52-week high of $431.32.

Young said:

“We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares.”

According to, Young is a 4-star analyst with an average return of 5.0% and a 47.3% success rate. Young covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Sarepta Therapeutics, and Puma Biotechnology.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $447.43.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $45.56B and has a P/E ratio of 26.90. The company has a Price to Book ratio of 5.79.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.